Spots Global Cancer Trial Database for AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Official Title: A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Study ID: NCT02675452
Study Description
Brief Summary: At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia
Detailed Description: This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia The study will be conducted in five parts.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope National Medical Center, Duarte, California, United States
University of California Davis Medical Center, Sacramento, California, United States
University of Colorado, Aurora, Colorado, United States
Northside Hospital, Atlanta, Georgia, United States
University of Chicago Hospital, Chicago, Illinois, United States
University Medical Center New Orleans, New Orleans, Louisiana, United States
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
Royal North Shore Hospital, St Leonards, New South Wales, Australia
The Alfred Hospital, Melbourne, Victoria, Australia
The Royal Melbourne Hospital, Parkville, Victoria, Australia
Tom Baker Cancer Centre, Calgary, Alberta, Canada
University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Universitaetsklinikum der Rheinisch-Westfaelischen Technischen Hochschule Aachen, Aachen, , Germany
Universitaetsklinikum Bonn, Bonn, , Germany
Universitaetsklinikum Ulm, Ulm, , Germany
Universitaetsklinikum Wuerzburg, Wuerzburg, , Germany
National Hospital Organization Nagoya Medical Center, Nagoya-shi, Aichi, Japan
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Fukuoka, Japan
National Hospital Organization Okayama Medical Center, Okayama-shi, Okayama, Japan
NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
